Blood Will Tell: Scientists Find Clues to Immunotherapy Responders and Non-Responders

[D.ap]

Summary
Some patients who receive immunotherapy drugs called checkpoint inhibitors experience significant benefit in terms of tumor shrinkage and longer survival — but many do not. A new study suggests that measuring changes in the blood could help doctors determine whether a person is likely to benefit from these drugs.

Highlights
Scientists analyzed changes in the blood of patients with melanoma treated with the immunotherapy drug pembrolizumab (Keytruda®).
They identified a biomarker that, when adjusted for the amount of cancer present, was correlated with outcomes to treatment.
Having a blood-based biomarker could enable doctors to learn early on whether a treatment is working for a particular patient.



https://www.google.com/amp/s/www.mskcc. ... ders%3famp

[D.ap]

Possibly the Ctc study could be a start for ASPS?
: )

http://www.cureasps.org/forum/viewtopic ... 564#p11956